Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial

Martin Bellgardt, Adrian Iustin Georgevici, Mitja Klutzny, Dominik Drees, Andreas Meiser, Philipp Gude, Heike Vogelsang, Thomas Peter Weber, Jennifer Herzog-Niescery, Martin Bellgardt, Adrian Iustin Georgevici, Mitja Klutzny, Dominik Drees, Andreas Meiser, Philipp Gude, Heike Vogelsang, Thomas Peter Weber, Jennifer Herzog-Niescery

Abstract

Background: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption of volatile anesthetics at 0.5 MAC (primary endpoint) and the corresponding costs. Secondary endpoints were the technical feasibility to reach and control the MAC automatically, the depth of sedation at 0.5 MAC, and awakening times. Mechanically ventilated and sedated patients after major surgery were enrolled. Upon arrival in the intensive care unit, patients obtained intravenous propofol sedation for at least 1 h to collect ventilation and blood gas parameters, before they were switched to inhalational sedation using MIRUS™ with isoflurane, sevoflurane, or desflurane. After a minimum of 2 h, inhalational sedation was stopped, and awakening times were recorded. A multivariate electroencephalogram and the Richmond Agitation Sedation Scale (RASS) were used to assess the depth of sedation. Vital signs, ventilation parameters, gas consumption, MAC, and expiratory gas concentrations were continuously recorded.

Results: Thirty patients obtained inhalational sedation for 18:08 [14:46-21:34] [median 1st-3rd quartiles] hours. The MAC was 0.58 [0.50-0.64], resulting in a Narcotrend Index of 37.1 [30.9-42.4] and a RASS of - 3.0 [- 4.0 to (- 3.0)]. The median gas consumption was significantly lowest for isoflurane ([ml h-1]: isoflurane: 3.97 [3.61-5.70]; sevoflurane: 8.91 [6.32-13.76]; and desflurane: 25.88 [20.38-30.82]; p < 0.001). This corresponds to average costs of 0.39 € h-1 for isoflurane, 2.14 € h-1 for sevoflurane, and 7.54 € h-1 for desflurane. Awakening times (eye opening [min]: isoflurane: 9:48 [4:15-20:18]; sevoflurane: 3:45 [0:30-6:30]; desflurane: 2:00 [1:00-6:30]; p = 0.043) and time to extubation ([min]: isoflurane: 10:10 [8:00-20:30]; sevoflurane: 7:30 [4:37-14:22]; desflurane: 3:00 [3:00-6:00]; p = 0.007) were significantly shortest for desflurane.

Conclusions: A target-controlled, MAC-driven automated application of volatile anesthetics is technically feasible and enables an adequate depth of sedation. Gas consumption was highest for desflurane, which is also the most expensive volatile anesthetic. Although awakening times were shortest, the actual time saving of a few minutes might be negligible for most patients in the intensive care unit. Thus, using desflurane seems not rational from an economic perspective. Trial registration Clinical Trials Registry (ref.: NCT03860129). Registered 24 September 2018-Retrospectively registered.

Keywords: Desflurane; Inhalational sedation; Isoflurane; MAC-driven sedation; Sevoflurane.

Conflict of interest statement

MB, AM, and JH-N received speakers’ honoraria from Pall Medical, Dreieich, Germany, the former owner of the MIRUS System in 2017 (1200 € each). The other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study design. After intravenous induction of anesthesia in the operating room, patients obtained a balanced anesthesia with sufentanil and sevoflurane at 1.0 MAC via a standard anesthetic machine during surgery. At the end of surgery, sedation was switched to an intravenous regime with propofol for the transport from the operating room to the intensive care unit (ICU). After a minimum of 1-h intravenous sedation in the ICU, patients obtained isoflurane, sevoflurane, or desflurane at 0.5 MAC via MIRUS™. As soon as the criteria for a wake-up test were met, a spontaneous breathing trail was performed. Once patients passed the test the MAC was set to 0. The dark blue lines mark the course of the MAC throughout the study
Fig. 2
Fig. 2
Awakening times. The time needed to decrease the MAC from 0.5 to 0.25 was longest for ISO (pink box) and quickest for DES (blue box). Correspondingly, awakening was quickest after DES sedation, followed SEVO (yellow box) and ISO. Median (horizontal black lines), 1st and 3rd quantile (upper and lower end of the boxes), the 95% interval (horizontal black lines) and statistical outliers (circles: outside the 95% interval) are presented. *DES is significantly quicker than ISO; #SEVO is significantly quicker than ISO

References

    1. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46:e825–e873. doi: 10.1097/CCM.0000000000003299.
    1. Baron R, Binder A, Biniek R, Braune S, Buerkle H, et al. Evidence and consensus based guideline for the management of delirium, analgesia, and sedation in intensive care medicine. Revision 2015 (DAS-Taskforce 2015)—short version. Ger Med Sci. 2015;13:19.
    1. Mesnil M, Capdevila X, Bringuier S, Trine PO, Falquet Y, Charbit J, et al. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med. 2011;37:933–941. doi: 10.1007/s00134-011-2187-3.
    1. Jerath A, Panckhurst J, Parotto M, Lightfoot N, Wasowicz M, Ferguson ND, et al. Safety and efficacy of volatile anesthetic agents compared with standard intravenous midazolam/propofol sedation in ventilated critical care patients: a meta-analysis and systematic review of prospective trials. Anesth Analg. 2017;124:1190–1199. doi: 10.1213/ANE.0000000000001634.
    1. Bomberg H, Glas M, Groesdonk VH, Bellgardt M, Schwarz J, Volk T, Meiser A. A novel device for target controlled administration and reflection of desflurane—the Mirus. Anaesthesia. 2014;69:1241–1250. doi: 10.1111/anae.12798.
    1. Herzog-Niescery J, Seipp HM, Weber TP, Bellgardt M. Inhaled anesthetic agent sedation in the ICU and trace gas concentrations: a review. J Clin Monit Comput. 2018;32:667–675. doi: 10.1007/s10877-017-0055-6.
    1. Nickalls RW, Mapleson WW. Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. Br J Anaesth. 2003;91:170–174. doi: 10.1093/bja/aeg132.
    1. Bellgardt M, Drees D, Vinnikov V, Procopiuc L, Meiser A, Bomberg H, et al. Use of the MIRUS™ system for general anaesthesia during surgery: a comparison of isoflurane, sevoflurane and desflurane. J Clin Monit Comput. 2018;32:623–627. doi: 10.1007/s10877-018-0138-z.
    1. Field A. Discovering statistic using SPSS. 4. London: SAGE Publications Ltd; 2014.
    1. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993;79:795–807. doi: 10.1097/00000542-199310000-00023.
    1. Kunst G. From coronary steal to myocardial, renal, and cerebral protection: more questions than answers in anaesthetic preconditioning? Br J Anaesth. 2014;112:958–960. doi: 10.1093/bja/aeu007.
    1. Bellgardt M, Bomberg H, Herzog-Niescery J, Dasch B, Vogelsang H, Weber TP, et al. Survival after long-term isoflurane sedation as opposed to intravenous sedation in critically ill surgical patients: retrospective analysis. Eur J Anaesthesiol. 2016;33:6–13. doi: 10.1097/EJA.0000000000000252.
    1. Meiser A, Groesdonk HV, Bonnekessel S, Volk T, Bomberg H. Inhalation sedation in subjects with ARDS undergoing continuous lateral rotational therapy. Respir Care. 2018;63:441–447. doi: 10.4187/respcare.05751.
    1. Rand A, Zahn PK, Schildhauer TA, Waydhas C, Hamsen U. Inhalative sedation with small tidal volumes under venovenous ECMO. J Artif Organs. 2018;21:201–205. doi: 10.1007/s10047-018-1030-9.
    1. Jerath A, Parotto M, Wasowicz M, Ferguson ND. Opportunity knocks? the expansion of volatile agent use in new clinical settings. J Cardiothorac Vasc Anesth. 2018;32:1946–1954. doi: 10.1053/j.jvca.2017.12.035.
    1. Herzog-Niescery J, Vogelsang H, Gude P, Seipp HM, Uhl W, Weber TP, Bellgardt M. Environmental safety: air pollution while using MIRUS™ for short-term sedation in the ICU. Acta Anaesthesiol Scand. 2019;63:86–92. doi: 10.1111/aas.13222.
    1. Romagnoli S, Chelazzi C, Villa G, Zagli G, Benvenuti F, Mancinelli P, et al. The new MIRUS system for short-term sedation in postsurgical ICU patients. Crit Care Med. 2017;45:925–931. doi: 10.1097/CCM.0000000000002465.
    1. Bomberg H, Groesdonk HV, Bellgardt M, Volk T, Meiser A. AnaConDa™ and Mirus™ for intensive care sedation, 24 h desflurane versus isoflurane in one patient. SpringerPlus. 2016;5:420. doi: 10.1186/s40064-016-2065-0.
    1. Meiser A, Bellgardt M, Belda J, Röhm K, Laubenthal H, Sirtl C. Technical performance and reflection capacity of the anaesthetic conserving device—a bench study with isoflurane and sevoflurane. J Clin Monit Comput. 2009;23:11–19. doi: 10.1007/s10877-008-9158-4.
    1. Bomberg H, Wessendorf M, Bellgardt M, Veddeler M, Wagenpfeil S, Volk T, et al. Evaluating the efficiency of desflurane reflection in two commercially available reflectors. J Clin Monit Comput. 2018;32:605–614. doi: 10.1007/s10877-016-9902-0.
    1. Meiser A, Sirtl C, Bellgardt M, Lohmann S, Garthoff A, Kaiser J, et al. Desflurane compared with propofol for postoperative sedation in the intensive care unit. Br J Anaesth. 2003;90:273–280. doi: 10.1093/bja/aeg059.
    1. Chanques G, Conseil M, Roger C, Constantin JM, Prades A, et al. Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-ventilation): a randomised, parallel-group clinical trial. Lancet Respir Med. 2017;5:795–805. doi: 10.1016/S2213-2600(17)30304-1.
    1. Eikermann M, Sarge TW. Postoperative interruption of sedation on arrival in the surgical ICU: a new standard of care. Lancet Respir Med. 2017;5:764–765. doi: 10.1016/S2213-2600(17)30350-8.

Source: PubMed

3
Tilaa